ArticleNeurology2013
Amyloid imaging: the court of public opinion.
Article in Neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 11 citations in OpenAlex.
- Impact of patient involvement on clinical practice guideline development: a parallel group study.Implementation science : IS · 2018Trial
- Returning aggregate research results to participants: a scoping review of current practices, preferences and challenges.BMJ open · 2025Article
- Participation and consultation engagement strategies have complementary roles: A case study of patient and public involvement in clinical practice guideline development.Health expectations : an international journal of public participation in health care and health policy · 2020Article
- Stakeholders' Views on Early Diagnosis for Alzheimer's Disease, Clinical Trial Participation and Amyloid PET Disclosure: A Focus Group Study.Journal of bioethical inquiry · 2019Article
- Amnestic MCI Patients' Perspectives toward Disclosure of Amyloid PET Results in a Research Context.Neuroethics · 2017Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human amyloid imaging is one of the great recent translational medicine stories. Beginning with the recognition that Thioflavin T derivatives could be used as PET tracers, through development of Pittsburgh compound B, to Food and Drug Administration (FDA) approval of Florbetapir in 2012, human amyloid imaging has held great promise to allow in vivo inclusive diagnosis of Alzheimer disease (AD), even though the first principle of amyloid PET is that it functions as a surrogate for β-amyloid pathology, and not necessarily as a surrogate for the diagnosis of AD.(1,2.)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.